The state of New York currently has 45 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
COVID-19 Survivorship Registry
Recruiting
COVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: NYU Langone Health, New York, New York
Conditions: Covid19
Antiviral Clinical Trial for Long Covid-19
Recruiting
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Long Covid
Humanity Neurotech Device Clinical Trial in Adults with Long COVID Cognitive Dysfunction
Recruiting
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Recruiting
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/29/2024
Locations: Synexus New York Site Number : 8400007, New York, New York
Conditions: COVID-19 Immunization, Influenza Immunization
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Recruiting
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for... Read More
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
11/14/2024
Locations: Suny University at Buffalo, Buffalo, New York +9 locations
Conditions: COVID-19
RECOVER-SLEEP: Platform Protocol
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Recruiting
This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: * Long Covid (LC) * Post-treatment Lyme disease syndrome (PTLDS) * Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: IMA Clinical Research - Albany, Suite 202, Albany, New York +3 locations
Conditions: SARS-CoV2, COVID-19
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
Recruiting
The Post-Acute Sequelae of SARS-CoV-2 (PASC) Autopsy Study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection in a diverse population representative of the general COVID-19 population in the US. The autopsy study will characterize the pathology of PASC in (i) non-hospitalized patients who die 30 days or later from symptom onset of COVID-19, and (ii) hospitaliz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: NYU Langone Health, New York, New York
Conditions: COVID-19, SARS CoV 2 Infection
A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx
Recruiting
For caregivers in the Bronx, the pandemic has caused unprecedented psychological distress; in addition to combating social determinants of health (SDOH), these families now face greater financial insecurity and challenges related to their school-aged children. Furthermore, social distancing requirements and limited telehealth resources for Bronx families have posed greater barriers to healthcare. Such parental distress contributes to heightened risk of transgenerational cycles of psychological s... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/28/2024
Locations: PRIME, Bronx, New York
Conditions: Parenting, Covid19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Community-acquired Pneumonia, Influenza, COVID-19